IMMP — Immutep Limited
Company context · prepared 2026-10-17 · company sweep 2026-10-17 · USD · framework v6.2.0
How to read this. Written for a curious reader with little or no background in science, medicine, the drug industry or finance. General terms are explained once in the glossary. All money figures are in US dollars (USD). Every fact carries one of three tags.
[VERIFIED — source]means a primary source confirmed it, and the source is named.[UNVERIFIED]means it could not be confirmed.[WEB ESTIMATE — source, date]means it is a third-party figure or a labelled model.Program analyses for this company are the sub-folders listed in C.2.
Two unit conventions, stated once. Immutep is an Australian company listed twice. Its ordinary shares trade in Australian dollars on the Australian Securities Exchange (ASX) under IMM. An American Depositary Share (ADS), a US-listed certificate standing for a fixed number of ordinary shares, trades on Nasdaq under IMMP. Since 2026-09-28 one ADS stands for 200 ordinary shares; before that it stood for 10. Every US-dollar price here is per ADS on the new basis. Australian-dollar figures are converted at AUD/USD 0.69588, the European Central Bank (ECB) reference cross rate for 2026-10-16
[WEB ESTIMATE — ECB reference rates via api.frankfurter.app, 2026-10-16].
C.0 Company-tier coverage — CLEARED
The company tier was re-run in full. The 2026-08-19 sweep was 59 days old, and the press feed has
since carried the FY26 annual results (2026-08-31) and an ADS ratio change, so it was not current
under 02-connectors.md § Company-sweep currency.
| Tool | State | Note / verbatim error |
|---|---|---|
BPIQ fetch_company_info | CALLED | Price, market capitalisation, 52-week range, cash, ownership. The 52-week fields are already restated for the ratio change. Enterprise value is unreconcilable (C.8). |
BPIQ fetch_company_drugs | CALLED | Nine rows, all in C.2. |
BPIQ fetch_company_historical_catalysts | CALLED | Called as fetch_all_historical_catalysts with tickers [IMMP], the form the connector now offers. 21 rows back to 2018. |
BPIQ fetch_company_options_data | CALLED | Completed with no output on three attempts. On 2026-08-19 it returned 28 contracts. Recorded as an empty result; see C.6. |
BPIQ fetch_company_insider_transactions | CALLED | Completed with no output on three attempts. The EDGAR filing feed agrees: no Form 4 filed. See C.5. |
BPIQ fetch_company_press_releases | CALLED | 229 items, latest 2026-10-15. |
optional BPIQ fetch_company_hedge_fund_holdings | CALLED | Empty object. |
optional BPIQ fetch_company_earnings_transcript | CALLED | No output. The FY26 annual report carried the management commentary. |
EDGAR submissions | CALLED | CIK 0001506184. Four 6-K filings since the last sweep were read in full (2026-09-02, 2026-09-11, 2026-09-22, 2026-10-14). No FY26 Form 20-F yet. |
EDGAR XBRL companyconcept (dei:EntityCommonStockSharesOutstanding) | CALLED | Latest value 1,460,389,575 at 2025-06-30. A year old, because the FY26 20-F is not yet filed. The current count, 1,473,721,306, comes from the FY26 annual report. |
FINRA consolidatedShortInterest | CALLED | Settlements 2026-08-14, 2026-08-31, 2026-09-15 and 2026-09-30 returned; 2026-10-15 not yet published. |
| optional Yahoo options chain | BLOCKED | Verbatim response body: Too Many Requests, on the crumb endpoint and on the chain endpoint, across two attempts several minutes apart. Cost: the empty BPIQ chain cannot be cross-checked. |
What this coverage does not cover. The price cache for this ticker exists now, but it is defective: it splices two price scales across the ratio change (C.8). Every figure below that reads price history says how it handled that.
C.1 What the company is
Immutep is an Australian biotechnology company built around one protein, lymphocyte activation
gene-3 (LAG-3). Its lead drug is eftilagimod alfa (efti), a soluble manufactured form of LAG-3
that switches the immune system on. Six of its nine pipeline rows are efti. The one separate asset
is IMP761, an antibody that uses LAG-3 to damp the immune system down in autoimmune disease. It has
no product revenue; its income is licence payments, research-material sales and research tax
incentives [VERIFIED — FY26 annual report, 6-K filed 2026-09-02].
What changed since 2026-08-19.
- A narrower plan for efti. On 2026-09-11 the company said registration-directed work will
focus on two settings only: head and neck cancer with no PD-L1 expression (CPS < 1), and soft
tissue sarcoma before surgery. Next trials are targeted for 2H CY2027, “subject to final
decisions on trial design, regulatory interactions, manufacturing timelines, partnering and
resources”
[VERIFIED — 6-K filed 2026-09-11]. - A manufacturing explanation for the Phase 3 failure. The same release says the root cause
analysis found “structural differences” between the efti used in TACTI-004 (made only at 2,000 L
scale) and the efti used in earlier positive trials (200 L scale), “e.g. a subtle difference in
N-glycan structure”. A new 200 L run is contracted. The analysis is not finished
[VERIFIED — 6-K filed 2026-09-11]. - An ADS ratio change. From 2026-09-28 one ADS stands for 200 ordinary shares instead of 10, to
cure a Nasdaq minimum-price deficiency. Nasdaq confirmed compliance on 2026-10-12
[VERIFIED — 6-K filed 2026-09-22; 6-K filed 2026-10-14].
The defining earlier fact still governs the valuation. On 2026-03-13 an independent data monitoring
committee stopped TACTI-004, the company’s only Phase 3, for futility. The ADS fell from US$2.76 to
US$0.48 on the old basis that day (US$55.20 to US$9.60 on the new basis) [VERIFIED — Immutep release 2026-03-13; data/prices/IMMP.json].
C.1a Delivery record and capabilities
| Item | Finding | Source / tag |
|---|---|---|
| Milestones met | EFTISARC-NEO: topline 27 days after registry primary completion (2025-04-30 to 2025-05-27); presented at ESMO 2025 (2025-10-20) and CTOS 2025 (2025-11-13) as guided; ESMO 2026 abstract on the date guided in July. TACTI-004: interim futility analysis held in Q1 CY2026 as guided (outcome negative). IMP761: single ascending dose phase completed and presented at EULAR 2026 (June). Nasdaq: compliance regained on 2026-10-12, before the 2026-10-26 deadline. | [VERIFIED — FY26 annual report; Immutep releases 2025-05-27, 2025-10-20, 2026-07-24; 6-K 2026-10-14] |
| Milestones missed or moved | TACTI-004 Phase 3 stopped for futility (2026-03-13). AIPAC-003’s Phase 3 portion terminated (closed 2026-06-30). The head and neck late-stage path, discussed with the FDA in 2025, has not started and is now a 2H CY2027 target. The investigator-led breast cancer trial planned to start 2026-09-01 is on hold. No catalyst date on EFTISARC-NEO has slipped. | [VERIFIED — Immutep releases 2026-03-13, 2026-09-11; CT.gov NCT05747794, NCT07102940] |
| Own manufacturing sites | None. Immutep keeps global manufacturing rights for efti but owns no plant. | [VERIFIED — FY26 annual report] |
| Contract manufacturers | One third-party vendor makes efti; the FY26 report does not name it. A$6,461,083 owed to it for manufacturing already performed is on deferred terms of up to 30 months, with interest. Ten GMP batches were made at 200 L; TACTI-004 used only 2,000 L product; a new 200 L run is contracted. The vendor’s name: no public record as of 2026-10-17. | [VERIFIED — FY26 annual report note 18; 6-K 2026-09-11] |
| Launch experience and sales force | None. No product has been sold and there is no sales force. | [VERIFIED — FY26 annual report] |
| Partnerships and licences | Dr. Reddy’s Laboratories SA, 2025-12-08: exclusive licence to efti outside North America, Europe, Japan and Greater China; US$20M upfront (US$10M repaid in June 2026 after TACTI-004), up to US$349.5M in milestones, double-digit royalties; Immutep supplies product. EOC Pharma: Greater China rights. Novartis (LAG525 antagonist antibody, licensed 2012): terminated by Novartis in August 2026. GSK (IMP731): technology transfer completed; data package under review. Merck & Co. supplies pembrolizumab to trials. | [VERIFIED — FY26 annual report; Dr. Reddy's release 2025-12-08] |
C.2 Pipeline — every program
| Program (drug — indication) | bpiq_drug_id | Stage & event | Catalyst (as disclosed) | Date to a day? | Analysed? | Materiality to the stock |
|---|---|---|---|---|---|---|
| Eftilagimod alfa — metastatic breast cancer (AIPAC-003) | 13585 | Phase 2/3 Update | TBA | No | No | Unfilled — not analysed. AIPAC-003 closed 2026-06-30; CT.gov lists it as terminated. |
| Eftilagimod alfa + pembrolizumab — soft tissue sarcoma (EFTISARC-NEO) | 17452 | Phase 2 Data readout | October 19, 2026 | Yes | Yes | Meaningful at the programme level, immaterial at the event level. Since 2026-09-11 it is one of the two indications the company intends to take into registration-directed trials, and it holds efti’s only Orphan Drug Designation. But this catalyst is a quality-of-life ePoster on a trial whose primary endpoint read out in May 2025. |
| Neoadjuvant eftilagimod alfa ± standard of care — early-stage HR+/HER2-negative breast cancer | 19277 | Phase 2 Update | TBA | No | No | Unfilled — not analysed. On hold pending the root cause analysis. |
| IMP761 (LAG-3 agonist antibody) — autoimmune disease | 18203 | Phase 1 Data readout | H2 2026 | No | No | Unfilled — not analysed. The 2026-08-19 version judged this row dominant. 03a-company-spec.md C.2 allows no judgement on an unanalysed row, so that judgement is withdrawn. |
| Eftilagimod alfa + KEYTRUDA + chemotherapy — 1L non-small cell lung cancer (INSIGHT-003) | 16013 | Phase 1 Update | TBA | No | No | Unfilled — not analysed. Mature median overall survival 30.9 months, single-arm (2026-07-13). |
| Eftilagimod alfa + avelumab — solid tumours, urothelial cancer | 18032 | Failed Discontinued | TBA | No | No | Unfilled — not analysed. Failed; kept as track record. |
| Eftilagimod alfa + KEYTRUDA — 1L non-small cell lung cancer (TACTI-004) | 13791 | Failed Discontinued | TBA | No | No | Unfilled — not analysed. Failed: stopped for futility 2026-03-13. BPIQ now sets has_catalyst false here; it was true on 2026-08-19. |
| IMP761 — COVID-19 | 14910 | Failed Discontinued | TBA | No | No | Unfilled — not analysed. Failed. |
| Eftilagimod alfa + KEYTRUDA — 1L head and neck squamous cell carcinoma (TACTI-003) | 18031 | Failed Discontinued | TBA | No | No | Unfilled — not analysed. BPIQ marks it failed, but the company named PD-L1-negative head and neck cancer as a registration-directed focus on 2026-09-11. See C.8. |
Two of nine rows carry a pending catalyst flag, and both are real: this program and IMP761.
C.3 Financial position
| Item | Value | As of | Tag |
|---|---|---|---|
| Cash and equivalents | A$68.87M (A$63.7M cash and equivalents plus A$5.2M term deposits) ≈ US$47.93M at 0.69588 | 2026-06-30 | [VERIFIED — FY26 annual report]; FX [WEB ESTIMATE — ECB reference rate, 2026-10-16] |
| Burn (per month) | Not disclosed as a forward rate. Q4 FY26 operating outflow was A$38.9M, including TACTI-004 spending and the US$10M Dr. Reddy’s repayment. This analysis models A$4M per month (A$12M per quarter, US$8.35M) for the September quarter, above the guidance-implied average because TACTI-004 close-out, A$13.4M of trade payables and a new manufacturing run fall in it. | Quarter to 2026-09-30, modelled | [UNVERIFIED — modelled from guidance] |
| Runway as the company states it | ”Well into the first half of CY2028” | 2026-08-31 | [VERIFIED — FY26 annual report] |
| Runway recomputed (cash ÷ burn) | At A$12M per quarter, about 5.7 quarters from 2026-06-30, to about 2027-10. The guidance implies about A$9.8M per quarter on average. | 2026-10-17 | [UNVERIFIED — derived] |
| Debt | No borrowings. Debt-like items: A$6.46M of interest-bearing deferred manufacturing payables (up to 30 months) and A$1.05M of leases; A$7.51M in all (≈ US$5.23M). The Ridgeback convertible notes converted in full on 2025-07-18. | 2026-06-30 | [VERIFIED — FY26 annual report notes 18, 19, 22] |
Dilution history. No equity raise in the last 24 months, and none announced or withdrawn. The
share count rose by 13.3M ordinary shares in FY26 (convertible-note conversion, warrant exercise,
vested performance rights) [VERIFIED — FY26 annual report note 23]. Funding came from the
Dr. Reddy’s licence instead.
| Date | Instrument | Gross proceeds | Price | Source |
|---|---|---|---|---|
| 2025-12-08 (received 2026-01) | Dr. Reddy’s licence upfront. Not equity | US$20M | n/a | [VERIFIED — FY26 annual report] |
| 2026-06 | Repayment of part of that upfront after TACTI-004 | −US$10M | n/a | [VERIFIED — FY26 annual report] |
| 2025-07-18 | Conversion of the last Ridgeback convertible notes: 7,441,304 shares at A$0.15 | nil cash | A$0.15 | [VERIFIED — FY26 annual report note 19] |
Is a raise before the next catalyst likely? Not before 2026-10-19. Before the 2H CY2027 trial
start, likely, unless a partner funds the trial. A raise with the ADS 27% below the cash floor would
be very dilutive [UNVERIFIED — judgement].
C.4 Valuation frame
| Item | Value | Source / tag |
|---|---|---|
| Share price (spot) | US$3.20 per ADS, the settled close of 2026-10-16 (≈ A$0.023 per ordinary share) | [VERIFIED — data/prices/IMMP.json via lib/prices.mjs closeOnOrBefore; BPIQ last_price 3.20, 2026-10-17] |
| Market capitalisation | US$23.58M: 1,473,721,306 ordinary shares ÷ 200 = 7,368,607 ADS-equivalents × US$3.20. BPIQ reports US$23,579,542, the same figure | [VERIFIED — FY26 annual report note 23 × spot] |
| Enterprise value | −US$19.1M: US$23.58M − US$47.93M cash + US$5.23M debt-like items. BPIQ reports −US$5,264,826, unreconcilable (C.8) | [UNVERIFIED — recomputed; depends on the FX rate and on the debt-like classification] |
| 52-week high / low | US$70.60 (2025-12-08) / US$3.06 (2026-10-15), on the new basis | [VERIFIED — lib/prices.mjs range52w on an adjusted series; BPIQ 70.60 / 3.06 agree] |
| Position in the 52-week range, computed off the last price | 0.2% | [VERIFIED — lib/prices.mjs positionInRange on the adjusted series] |
| Multiple off the 52-week low | 1.05× | [VERIFIED — 3.20 ÷ 3.06] |
| Economic share count | 7,452,053 ADS-equivalents: (1,473,721,306 ordinary shares + 16,689,221 nil-price performance rights) ÷ 200. No options, warrants or convertibles on issue | [VERIFIED — FY26 annual report notes 23 and 34, at 2026-06-30] |
How the range was produced. The committed cache splices two price scales (C.8). Run as
03a-company-spec.md C.4 instructs, range52w and positionInRange on the raw cache return a low
of 0.26, a high of 7.00 and a position of 43.6%, all wrong. The figures above come from the same two
calls on an adjusted copy: every bar before 2026-09-28 multiplied by 20, except the 2026-09-14 bar,
which is already on the new basis. The adjusted figures match BPIQ’s restated 52-week fields.
What the numbers say in plain terms. The market values the whole company at about US$19M less
than its June cash net of debt-like items. Net of the modelled burn to 2026-10-19, the cash floor is
US$4.37 per ADS, and spot sits 27% below it (lib/edge.mjs cashFloor; inputs above). The
ADS has fallen 60% since 2026-08-19: US$0.40 then on the old basis is US$8.00 on the new basis. The
fall came in two steps. After the 2026-09-11 strategy release the ADS fell 30% in ten sessions. After
the ratio change took effect it fell another 32% in thirteen sessions.
The listing deadline, resolved. Nasdaq notified Immutep on 2026-04-27 that its ADS had closed
below US$1.00 for 30 business days. The ratio change of 2026-09-28 lifted the price above US$1.00,
and Nasdaq confirmed compliance on 2026-10-12 after ten qualifying sessions, 2026-09-28 to
2026-10-09 [VERIFIED — 6-K filed 2026-10-14]. The company notes that a new deficiency within 12
months of a ratio change gets no fresh compliance period, which is why it chose a large ratio
[VERIFIED — 6-K filed 2026-09-22]. At US$3.20 the margin above US$1.00 is still large.
C.5 Ownership and flow
| Holder type | Share | Note | Source |
|---|---|---|---|
| Insider | 0.012% | Unchanged from 2026-08-19; describes US filers only | [VERIFIED — BPIQ fetch_company_info, 2026-10-17; no timestamp] |
| Institutional | 1.13% | Same caveat | [VERIFIED — BPIQ fetch_company_info, 2026-10-17; no timestamp] |
| Retail / other | ~98.9% residual | Not a measured figure | [UNVERIFIED — residual] |
| Short interest | 46,784 ADS = 2.85% of the ~1.64M ADS on issue (0.63% of all ADS-equivalents); days to cover 2.03 | Settlement 2026-09-30, new basis | [VERIFIED — FINRA consolidatedShortInterest; ADS count from 6-K filed 2026-09-22] |
Read the split with the dual listing in mind. Only about 1.64M ADS exist after the ratio change, about 22% of the company. The rest trades as ordinary shares on the ASX, mostly held by Australian holders who file with neither the SEC nor on a 13F. A 1.13% institutional reading describes the American slice.
Short interest is small and the ratio change distorts FINRA’s own arithmetic. FINRA’s change of −95.18% between 2026-09-15 (971,238 ADS) and 2026-09-30 (46,784 ADS) compares two bases. On one basis 971,238 ÷ 20 = 48,562, so the real change is about −3.7%. Correction to the 2026-08-19 version: it divided its short count by all ordinary shares expressed as ADS (146M) and called the result 0.82% “of ADS outstanding”. The ADS line then on issue was about 32.8M, so that short was about 3.6% of the ADS line. There is no squeeze set-up either way.
Liquidity is very thin. Over the 14 sessions on the new basis, the ADS traded about 21,700 ADS a
day, about US$86,000 [VERIFIED — data/prices/IMMP.json].
Insider flow: nothing reported. BPIQ returned nothing three times. EDGAR shows six Form 3
initial statements filed 2026-04-01 to 2026-04-16, every one with event date 2026-03-18, and no
Form 4 at any time [VERIFIED — EDGAR submissions, 2026-10-17]. So no director or officer has
reported a trade to the SEC since. ASX director-interest notices (Appendix 3Y) were not read. No
open-market buying at a price 27% below cash is visible.
Nobody is positioned through a fund. hf_holding_count is 0 and the holdings call returns an
empty object [VERIFIED — BPIQ, 2026-10-17].
C.6 Options chain and its readability
Plain takeaway: there is no options chain to read. BPIQ returned no chain on three attempts. After a ratio change, existing contracts are normally converted into adjusted contracts on the old deliverable, so a standard chain may genuinely not exist yet. The optional Yahoo cross-check was throttled, so this could not be confirmed. Either way, no options market would price an event on an ADS line trading US$86,000 a day.
| Item | Value | Note |
|---|---|---|
| Spot | US$3.20 | Settled close 2026-10-16 |
| Nearest listed strike to spot | none returned | BPIQ no output ×3 |
| Expiry nearest the next catalyst | none returned | |
| At-the-money straddle ÷ spot | not computable | |
| Front implied volatility | unreadable | |
| Open interest at that strike | none returned | |
| Liquidity confidence | None |
C.7 Reaction to past catalysts
The move columns: BPIQ’s intraday figure where it has one, and the event-window move from the price
cache through lib/prices.mjs: the average of the two closes before the announcement day against
the average of the announcement-day close and the next close. Every window lies wholly before the
2026-09-28 ratio change, so both ends share one basis; the 2026-09-14 bar is excluded from the one
window it touches. This is new: the 2026-08-19 sweep had no cache and could not size four of these
rows.
| Date | Event | Intraday move | Same-day press-feed check | Read |
|---|---|---|---|---|
| 2026-09-21 | ADS ratio change announced | n/a; window −6.56% | One release and a 6-K | A technical change, sold. The slide continued after it took effect: −32% over 13 sessions. |
| 2026-09-11 | Focused efti strategy; next trials 2H CY2027; manufacturing finding | n/a; window +1.45%, day +12.1% on 3.2M ADS | One release and a 6-K | The day rewarded a path; the next ten sessions fell 30% as the wait and the unfunded trials were priced. |
| 2026-07-24 | ESMO 2026 abstract accepted (this catalyst) | n/a; window −2.56% | Clean | The acceptance of this very abstract moved the stock down. |
| 2026-07-13 | INSIGHT-003 mature survival, bundled with a TACTI-004 update | +6.88%; window +4.76% | One combined release | Positive, modest, bundled. |
| 2026-06-04 | IMP761 interim Phase 1 at EULAR | −4.64%; window −7.23% | Clean | Positive data, stock down: sell-the-news. |
| 2026-05-28 | Pooled five-trial lymphocyte and survival analysis | −0.65%; window 0.00% | Clean | No reaction to a secondary analysis. |
| 2026-04-15 | FDA Orphan Drug Designation, soft tissue sarcoma | −46.14% (from the open); window +80.65% | Heavy coverage; 704M ADS traded | The largest positive move, and it was on sarcoma. Correction to the 2026-08-19 version, which recorded it as unreadable: the cache shows a close of 0.31 before, an open near 1.00 and closes of 0.54 and 0.58. BPIQ’s +221% gap and −46% intraday were both right. It faded to 0.43 by late May. |
| 2026-03-13 | TACTI-004 stopped for futility | −11.89%; window −82.79% | Five same-day items; no offering | The defining move. |
| 2025-12-22 | IMP761 positive Phase 1 update | +0.73%; window +8.76% | Clean | The intraday figure understated the move. |
| 2025-11-13 | CTOS 2025: EFTISARC-NEO translational data | n/a; window +3.36% | One release | Modest positive. |
| 2025-10-20 | ESMO 2025: full EFTISARC-NEO primary data | n/a (BPIQ omits the row); window −1.68% | One release | The closest precedent for 2026-10-19: the same trial and congress, headline already public. |
| 2025-05-27 | EFTISARC-NEO met its primary endpoint | null in BPIQ; window +0.26% | One release; US closed 2025-05-26 | The trial’s real result barely moved the stock. |
| 2024-11-14 | CTOS 2024: first EFTISARC-NEO data | +7.69%; window +7.53% | One release | The first sarcoma data drew the largest sarcoma-congress reaction. |
What the rows say together. The median window move across the eight clean, non-registrational data events (2024-11-14, 2025-05-27, 2025-10-20, 2025-11-13, 2025-12-22, 2026-05-28, 2026-06-04, 2026-07-13) is +1.81%. The four EFTISARC-NEO data events alone have the same median. This stock does not pay for incremental good data. It paid enormously for one regulatory fact (the orphan designation) and punished one failure catastrophically.
Rows missing from BPIQ. fetch_company_historical_catalysts omits the 2025-10-20 ESMO 2025
presentation, the 2026-09-11 strategy release and the 2026-09-21 ratio change.
C.8 Company data-quality flags
- The price cache splices two scales (named data defect).
data/prices/IMMP.jsonholds bars to 2026-09-25 on the old basis (1 ADS = 10 ordinary) and bars from 2026-09-29 on the new basis (1 ADS = 200). 2026-09-28, the effective date, is a null bar, although Nasdaq counted it as a qualifying session. 2026-09-14 is a lone new-basis bar (close 6.60, volume 25,415) between two old-basis bars (0.37 and 0.33); 6.60 ÷ 20 = 0.33. The fetch of 2026-10-17 reported that the source now returns old bars at 20 times their stored values, and the fetcher never overwrites. Anylib/prices.mjscomputation that spans 2026-09-28 reads mixed scales. This document adjusts explicitly where it uses one (C.4) and keeps every C.7 window on one side. The cache was not repaired: it is outside this analysis’s lane. - An intraday bar is frozen in the cache: 2026-08-19 stored at 0.3964 on volume 44,352, against a source close of 0.39.
- The corporate action is confirmed from primary sources: ratio 1:10 to 1:200, effective 2026-09-28, CUSIP 45257L108 to 45257L207, depositary BNY, ordinary shares unchanged at 1,473,721,306 (6-K filed 2026-09-22; completion confirmed in the 6-K filed 2026-10-14).
- FINRA’s change figure spans the ratio change (−95.18% reported against about −3.7% real).
- BPIQ
enterprise_value(−5,264,826) is unreconcilable. Itscash(68,873,044) is in A$ whilemarket_capis in US$, as on 2026-08-19. - BPIQ options and insider calls returned no output three times each. The insider result agrees with EDGAR. The options result could not be cross-checked.
- BPIQ and the company disagree on head and neck cancer. Row 18031 is marked failed; the 2026-09-11 release makes PD-L1-negative head and neck cancer a registration-directed focus with Fast Track designation. Left unresolved.
- EDGAR XBRL’s share count is a year old (2025-06-30); the FY26 20-F is not yet filed.
- BPIQ’s historical-catalyst feed is incomplete (C.7), and its intraday field can understate a two-day move (2025-12-22).
- BPIQ
has_catalyston row 13791 is now false. The stale flag recorded on 2026-08-19 is fixed. - Correction: the 2026-08-19 short-interest percentage used the wrong denominator (C.5).
- Correction: the 2026-08-19 orphan-designation move is readable (C.7).
- Drug names remain dirty (leading and trailing spaces; several spellings of one molecule). Nothing is keyed on them.
- BPIQ
insider_ownandtute_owncarry no timestamp.